Share on StockTwits

Stock analysts at Stifel Nicolaus initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Monday, reports. The firm set a “buy” rating and a $11.00 price target on the stock. Stifel Nicolaus’ price target indicates a potential upside of 36.82% from the company’s current price.

Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Marinus Pharmaceuticals in a research note on Monday. They set a “buy” rating on the stock.

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 8.04 on Monday. Marinus Pharmaceuticals has a one year low of $8.00 and a one year high of $8.16. The stock has a 50-day moving average of $8.02 and a 200-day moving average of $8.02. The company’s market cap is $4.0 million.

Marinus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing neuropsychiatric therapeutics.

The Fly On The Wall

Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.